Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
$121.9M
Market Cap • 11/18/20242010
(14 years)
2016
(8 years ago)
NASDAQ
Listing Exchange
Iselin
Headquarters • New JerseyPremium
...and much more!